A REVIEW ON NOSE TO BRAIN DRUG DELIVERY SYSTEM

1 Sohel Baig Mukhtar Baig, 2 Altamash Harun Khatik, 3 Sonavane Vaibhav Mahendra, 4 Shruti Pradip Sonawane, 5 Prof. Pradnya R. More
OBVS's Prof. Ravindra Nikam College of Pharmacy, Gondur-Dhule-424002, Maharashtra, India.
Kavayitri Bahinabai Chaudhari North Maharashtra University Jalgaon, Maharashtra, India.

Abstract: A potentially effective method of bypassing the barrier between the blood and the brain and delivering medicinal substances straight to the brain is the nose-to-brain medication delivery system. The state-of-the-art in nose-to-brain medication delivery systems is thoroughly reviewed in this paper, with an emphasis on recent developments, difficulties, and potential future directions. The nasal route has several benefits for delivering drugs to the brain, such as a rich blood supply, a wide surface area, and the ability to bypass first-pass metabolism. To improve medication transport through the nasal passages to the brain, a number of approaches have been investigated, such as the use of mucoadhesive formulations, nasal irrigation methods, and nanocarriers.

The efficiency & targeting abilities of nose to brain delivery systems are significantly enhanced by nanotechnology. Medications may be delivered continuously and with regulated release thanks to nanocarriers including liposomes, nanoparticles, and nano emulsions, which also increase the medications’ bioavailability and therapeutic effectiveness. By limiting systemic adverse effects, surface modification approaches enable tailored delivery to certain brain areas. By maintaining longer contact with the nasal mucosa and facilitating absorption into the systemic circulation or direct transfer to the brain, mucoadhesive formulations improve medication retention in the nasal cavity. Mucoadhesive systems based on polymers, such hydrogels and microspheres, have shown potential in enhancing medication absorption and retention. Nasal irrigation methods provide a non-invasive and patient-friendly way to administer medication. These methods include nasal sprays and nebulizers. By administering medications in an aerosolized form, these devices enable quick absorption through the nasal epithelium and direct delivery of the medication to the brain through the olfactory and trigeminal pathways.

Even with great advancements, there are still a number of issues with nose-to-brain medication administration that need to be resolved, such as the removal of nasal mucociliary cells, the breakdown of enzymes, and architectural obstructions in the nasal canal. In addition, a thorough assessment of the long-term impacts on the nasal mucosa and the safety profile of nanocarriers is required. Neap-to-brain medication delivery devices are particularly promising for treating Parkinson's disease, Alzheimer's disease, and brain tumors, among other neurological conditions. To fully realize the promise of this novel technique in clinical practice, more study is needed to overcome current obstacles and optimize delivery strategies.

1. INTRODUCTION

The blood-brain barriers (BBB), a highly selective membrane that prevents the majority of molecules from the circulation from passing into the brain parenchyma, makes the delivery of therapeutic medicines to the brain an extremely difficult task. Because of the BBB's limited permeability, conventional drug delivery techniques like oral medication or intravenous injection frequently cause minimal brain uptake and systemic adverse effects.
The nose to brain drug delivery system has become a viable substitute for going around the BBB and giving medications straight to the brain in recent years. This novel method makes use of the nasal cavity's distinct anatomical and physiological characteristics, which include its extensive vascularization, which gives medications a direct route to the central nervous system (CNS).

The nasal route is advantageous for delivering drugs to the brain since it avoids first-pass metabolism, acts quickly, and doesn't need invasive administration. Furthermore, due to its high permeability and the presence of trigeminal and olfactory nerve terminals, the nasal mucosa facilitates the direct delivery of medications to the brain through neural pathways.

Drug delivery from the nasal passages to the brain has been improved by a number of approaches, such as nasal irrigation, mucoadhesive formulations, and nanotechnology. Drug delivery and controlled release are made possible by nanocarriers like liposomes, nanoparticles, and nanoemulsions. Mucoadhesive formulations, on the other hand, extend the retention of medications in the nasal cavity, improving absorption and bioavailability.

Notwithstanding these developments, a number of issues with nose-to-brain medication transport still need to be resolved, such as possible toxicity of nanocarriers, enzymatic degradation, and nasal mucociliary clearance. Furthermore, clinical and preclinical research must thoroughly assess the safety and effectiveness of various delivery methods.

Nose-to-brain medication delivery devices are a promising new avenue for treating a variety of neurological conditions, such as brain tumors, Parkinson's disease, and Alzheimer's disease. To solve current problems and improve the delivery methods for clinical translation, more research is needed. The purpose of this study is to encourage more research in the quickly developing field of nose-to-brain medication delivery while offering insightful information about the state of the art.

Nasal Anatomy And Physiology

An essential component of our respiratory system is the nasal cavity. Key details regarding its anatomy are as follows:

External Nose:
The most noticeable part on our face is the outside nose. It is composed of cartilaginous and bony elements.

The nose’s peak is situated inferiorly, while its root is superior.
The dorsum of the nose is the region that is between the root and the apex.
The nasal cavity's entrances, known as the nares (nostrils), are situated under the apex. The nasal septum divides them, and the ala nasi, or nostril wings, enclose them laterally.

Nasal Cavity:
The interior portion of the nose is called the nasal cavity. It performs a number of crucial tasks:

Respiration: Breathing is made easier by respiration, which permits air to enter and depart.
Olfaction (Sense of Smell): The nasal cavity's olfactory area is responsible for detecting different smells.
Speech: The nasal cavity contributes to the creation of speech.
Taste: It's interesting to note that our sense of smell accounts for around 80% of taste. Food might appear nearly unpalatable when our noses are congested!
Three areas comprise the nasal cavity:

- **Vestibule:** The area in front of the nose.
- **Respiratory Region:** The area with air conditioning (warm and humidified) is known as the respiratory region.
- **Olfactory Region:** The olfactory region has specific cells that are responsible for identifying scents.

**Blood Supply:**

- The internal and external carotid arteries provide blood to the nasal cavity.
- The sphenopalatine, larger palatine, superior labial, and lateral nasal arteries are branches of the external carotid artery.
- The anterior and posterior ethmoidal arteries are branches of the internal carotid artery.

**Nerve Supply:**

- The sensation of smell is provided by the olfactory nerve.
- General feeling is provided by the trigeminal nerve.
- Serous gland secretion is controlled by the facial nerve (parasympathetic regulation).
- Mucosal blood flow is influenced by sympathetic control at the T1 level of the spinal cord.

### II. NASAL PHYSIOLOGY

- **Air Filtration:** Dust, pollen, and other particles are captured by the nasal hairs and mucosal membranes when air enters the nasal cavity.

- **Humidification:** Mucus is secreted by the nasal mucosa, which moisturizes the air and aids in preserving the ideal humidity level for the respiratory system.

- **Temperature Regulation:** In order to prevent respiratory tract discomfort, the nasal turbinates’ warm the air as it travels through the nasal cavity and bring it to body temperature.

- **Olfaction:** The sense of smell is made possible by the olfactory receptors in the olfactory epithelium, which identify odor molecules in the atmosphere and send messages to the brain.

- **Nasal Mucociliary Clearance:** The cilia, which resemble hair-like structures, found in the nasal mucosa beat rhythmically and continually to push trapped particles and mucus toward the back of the throat, where they are either ingested or ejected.

### III. OBJECTIVES

A nose-to-brain drug delivery system's primary goal is to deliver therapeutic medications straight to the brain by avoiding the blood-brain barrier (BBB). The blood-brain barrier (BBB) is an extremely selective barrier that controls the flow of chemicals from the circulation into the brain. While it shields the brain from dangerous chemicals and infections, it also makes it more challenging to provide medications that cure neurological illnesses.

Using the special anatomical characteristics of the nasal canal, nose-to-brain drug delivery transports medications straight to the brain. There are two primary areas of the nasal cavity:

- The area of the olfactory nerves, which have direct connections to the brain.
- The respiratory area permits chemicals to be absorbed into the circulation since it is bordered by a thin layer of epithelium.
The goal of nose-to-brain drug delivery is to administer medications either via the respiratory epithelium or the olfactory nerve route. The precise goals of employing a nose-to-brain medicine delivery system are as follows:

- **Deliver drugs directly to the brain:** When compared to oral or intravenous administration, nose-to-brain drug delivery may be able to deliver larger concentrations of medications to the brain by avoiding the blood-brain barrier.

- **Improve bioavailability:** Bioavailability is the percentage of a medication that gets into the bloodstream and gets to its intended location. Drug administration via the nose to the brain can increase bioavailability by circumventing first-pass metabolism, the process by which medications are metabolized by the liver prior to entering the circulation.

- **Reduce systemic side effects:** Because nose-to-brain medication administration directly targets the brain, it may be able to lessen systemic adverse effects that may arise from drug distribution throughout the body.

- **Treat neurological diseases:** A potential treatment strategy for a number of neurological conditions, including as schizophrenia, Parkinson's disease, and Alzheimer's disease, is nose-to-brain medication administration.

### IV. ADVANTAGES

The nose-to-brain drug delivery system offers several distinct advantages over traditional routes of drug administration, particularly for the treatment of neurological disorders. Some of these advantages include:

1. **Bypassing the Blood-Brain Barrier (BBB):** One major benefit of nose-to-brain drug delivery is its capability to bypass the BBB, a highly selective barrier that hinders numerous drugs from reaching the brain. By directly administering drugs to the brain through the olfactory or trigeminal nerve pathways, this method overcomes the obstacles related to BBB permeability.

2. **Enhanced Drug Delivery Efficiency:** Nasal administration offers a direct and quick pathway for delivering drugs to the brain, leading to higher drug concentrations in the desired area compared to systemic administration. This can enhance therapeutic results and decrease systemic side effects.

3. **Rapid Onset of Action:** Drugs administered through the nose-to-brain pathway typically have a quicker onset of action than when given orally or intravenously. This is especially beneficial for addressing acute neurological conditions that require prompt symptom relief.

4. **Reduced Systemic Side Effects:** Nasal-to-brain drug administration reduces the amount of time that medications are exposed to other tissues and organs, which lowers the possibility of systemic adverse effects. This is particularly crucial for medications with short therapeutic windows or significant toxicity.

5. **Non-Invasive Administration:** Nasal medication administration is appropriate for long-term therapy regimens since it is non-invasive and well-tolerated by patients. This can enhance therapeutic adherence and patient compliance, especially in populations like the elderly or children.

6. **Potential for Targeted Delivery:** Drug delivery technology now makes it possible to deliver drugs specifically to certain parts of the brain by nasal administration. This means that precision medicine strategies can be tailored to each patient's individual needs.

7. **Versatility and Flexibility:** The anatomical landscape along the nose-to-brain pathway is quite vast, and can accommodate many forms of drug delivery, including small molecules, peptides, proteins as
well as gene-based therapies. Essentially, this approach can be used to deliver a great number of therapeutics in the treatment of a wide range of neurological diseases.

8. **Cost-Effectiveness:** Nasal drug delivery systems are mostly non-invasive, and therefore the cost of delivering the drug is lower as compared to systemic forms of drug administration or invasive approaches. Consequently, these systems can contribute towards low healthcare cost and improved scope of treatment for patients.

V. LIMITATION

While the nose-to-brain drug delivery system offers many advantages, it also has several limitations and challenges that need to be addressed:

1. **Limited Drug Compatibility:** Not all drugs are suitable for nasal administration for several reasons, including molecular size, hydrophobicity, and chemical stability. There are also drugs that might not effectively cross the nasal epithelium or that might be degraded in the nasal cavity, thus reducing their efficiency.

2. **Nasal Mucociliary Clearance:** There is the nasal mucociliary clearance mechanism that removes foreign substances and drugs rapidly from the nasal cavity, which reduces their absorption and residence time. On the other hand, drugs may need to deal with mucociliary clearance first, especially if they are not absorbed in the first pass. Hence nasal irrigation techniques and mucoadhesive formulations that can bypass the mucociliary clearance are required.

3. **Enzymatic Degradation:** Enzymes occurring in the nasal mucosa can break down drugs before they get to the systemic circulation or the brain. Enzyme inhibitors or prodrug approaches can therefore be used to minimize enzymatic degradation and enhance drug stability.

4. **Anatomical Variability:** Inter-individual heterogeneity of nasal anatomical and physiological parameters lead to differences in drug bioavailability. For instance, nasal septal deviation, nasal congestion or mucosal inflammation could affect the efficiency and reproducibility of drug delivery.

5. **Nasal Irritation and Adverse Effects:** Certain drug formulations or delivery devices can produce nasal irritation, discomfort, or AEs such as rhinitis or epistaxis. Patient acceptability and tolerance for nasal delivery should be a major concern while creating new therapies.

6. **Limited Targeting Precision:** Although nasal delivery directly accesses the brain, the key challenge remains to target specific areas within the brain. Developing strategies for precise targeting and reduced off-target effects will be essential for a balance between therapeutic efficacy and minimizing side-effects.

7. **Safety Concerns with Nanocarriers:** Concerns over safety issues such as biocompatibility, toxicity and nasal mucosa toxicity upon long-term use of nanocarriers used in nasal drug delivery like nanoparticles and liposomes. Prior to clinical translation of nanotechnology-based delivery systems, comprehensive safety evaluations are critical.

8. **Regulatory Hurdles:** Regulatory approval of new nasal drug delivery systems may face challenges as there are no well-established testing methods or regulatory guidelines. It is important for researchers to work closely with regulatory authorities and industry partners to identify the best approach to get the marketing approval faster.
VI. FACTORS AFFECTING DELIVERY IN NOSE-TO-BRAIN DRUG DELIVERY SYSTEMS

A nose-to-brain medication delivery system's efficacy depends on a number of sensitive interactions. Below is a summary of the major factors affecting medication delivery:

1. Drug Properties:
   - **Solubility**: To aid with absorption, medications must be easily soluble in nasal secretions. Meds with poor solubility may have trouble passing through the nasal mucosa.
   - **Molecular Weight**: To effectively pass through the nasal epithelium, medications should ideally have a molecular weight of less than 500 Daltons. Bigger molecules may find it more difficult to pass over this barrier.
   - **Mucus Interaction**: As a drug is removed via the mucociliary escalator (mucus transport system), it may have a lower absorption rate if it binds substantially to mucus.

2. Formulation Factors:
   - **Particle Size**: Drug contact with the nasal mucosa is improved and absorption may be enhanced by smaller particles since they have a bigger surface area.
   - **Charge**: Medicines with a positive charge may interact with the nasal mucosa than those with a negative charge, encouraging adhesion as well as boosting absorption.
   - **Excipients**: Penetration enhancers, for example, are common excipients used in formulations that temporarily break the tight connections of the nasal epithelium to allow for the passage of drugs.

3. Nasal Physiology:
   - **Mucus Production**: An excessive amount of mucus might obstruct the absorption of drugs by acting as a barrier. On the other hand, inadequate mucus might cause nose irritation and shorten the duration of medication residence.
   - **Mucociliary Clearance**: This is the process by which mucus carrying particles that have become stuck moves toward the back of the throat. A quick clearance rate can shorten the duration of a drug's residency in the nasal cavity and decrease absorption.
   - **Nasal Blood Flow**: Drug absorption into the circulation and subsequent brain transport are facilitated by adequate blood flow in the nasal cavity. Excessive blood flow, however, may cause the medication solution to drain before any real absorption takes place.

4. Additional Considerations:
   - **Patient Variability**: A person's nasal anatomy and physiology may differ from another person's due to age, allergies, or past nasal surgery. The efficiency of drug delivery may be impacted by this variability.
   - **Drug Degradation**: Certain enzymes found in the nasal cavity can breakdown medications, lowering their effectiveness. Formulations may need to integrate methods to protect medications against enzymatic degradation.

VII. THE COMPARISON BETWEEN NASAL DRUG DELIVERY SYSTEM AND ORAL, PARENTERAL AND TRANSDERMAL DRUG DELIVERY:

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Nasal Drug Delivery</th>
<th>Oral Drug Delivery</th>
<th>Parenteral Drug Delivery</th>
<th>Transdermal Drug Delivery</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Route of Administration</strong></td>
<td>Nasal cavity</td>
<td>Oral cavity</td>
<td>Injection (intravenous, intramuscular, subcutaneous)</td>
<td>Skin</td>
</tr>
<tr>
<td><strong>Drug Absorption Site</strong></td>
<td>Nasal mucosa</td>
<td>Gastrointestinal tract</td>
<td>Bloodstream</td>
<td>Skin</td>
</tr>
<tr>
<td><strong>Absorption Rate</strong></td>
<td>Rapid</td>
<td>Variable, affected by gastrointestinal</td>
<td>Rapid, immediate onset of action</td>
<td>Slow and sustained</td>
</tr>
<tr>
<td></td>
<td>First-Pass Metabolism</td>
<td>Bioavailability</td>
<td>Onset of Action</td>
<td>Patient Compliance</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>factors (e.g., pH, transit time)</td>
<td>Partial bypassed</td>
<td>Extensive, significant metabolism in the liver</td>
<td>Bypassed</td>
<td>Variable, depending on drug and skin characteristics</td>
</tr>
<tr>
<td></td>
<td>Bioavailability</td>
<td>Moderate to high</td>
<td>Variable, affected by factors such as drug solubility, stability, and formulation</td>
<td>Complete (for intravenous administration)</td>
</tr>
<tr>
<td></td>
<td>Onset of Action</td>
<td>Rapid</td>
<td>Variable, affected by drug dissolution and absorption</td>
<td>Immediate (for intravenous administration)</td>
</tr>
<tr>
<td></td>
<td>Patient Compliance</td>
<td>Generally good, non-invasive route</td>
<td>Good, convenient and familiar</td>
<td>Variable, may require healthcare professional administration</td>
</tr>
<tr>
<td></td>
<td>Dosing Flexibility</td>
<td>Limited by volume and absorption capacity of nasal cavity</td>
<td>Flexible dosing options, but influenced by patient adherence</td>
<td>Flexible dosing options</td>
</tr>
<tr>
<td></td>
<td>Local vs. Systemic Effects</td>
<td>Can be targeted locally to nasal or brain tissues</td>
<td>Primarily systemic effects, some drugs may target specific organs or tissues</td>
<td>Primarily systemic effects, some drugs may target specific organs or tissues</td>
</tr>
<tr>
<td></td>
<td>Suitability for Biologics</td>
<td>Suitable for small molecules, peptides, proteins, and gene-based therapies</td>
<td>Limited for large molecules due to enzymatic degradation and poor absorption</td>
<td>Suitable for all types of drugs, including biologics</td>
</tr>
<tr>
<td></td>
<td>Risk of Infection</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Regulatory Approval</td>
<td>May require specific guidelines for nasal drug delivery</td>
<td>Generally well-established regulatory pathways</td>
<td>Well-established regulatory pathways</td>
</tr>
</tbody>
</table>
**BACKGROUND:**

An emerging approach that has garnered interest in the last few years is the nose-to-brain drug delivery system, which offers the potential to cross the blood-brain barrier and allow therapeutic agents to target the brain directly. The BBB is one of the most severe challenges in managing neurological conditions due to its ability to limit many drugs from passing from the bloodstream to the brain parenchyma.

Conventional drug delivery involves routes like oral ingestion or systemic injection, which usually cause poor drug concentration in the brain and high systemic exposure that is usually associated with poor drug efficacy and possibly systemic side effects due to inefficiency of the and the brain-blood barrier. However, in comparison, with the nose to brain route is based on the direct and targeted delivery of drugs to the central nervous system through the olfactory and the trigeminal nerve pathways.

The nose is a well-vascularized organ with a very big surface area covered by a thin mucous membrane which makes it the preferred channel for drug delivery. Drugs given intranasally can avoid the blood-brain barrier and quickly enter the brain bringing about higher local levels and lower systemic exposure.

To improve drug delivery from the nasal cavity to the brain, many approaches have been tried. These include nanotechnology, mucoadhesive formulations and nasal irrigation methods. Nanoparticles, liposomes and nanoemulsions are some examples of nanocarriers that can be used for drug release at specific sites within the body. It is also possible to use mucoadhesive substances in order to increase absorption through prolonged retention time in the nose. Such strategies can greatly enhance local drug availability which would be very useful for treating diseases like Alzheimer’s or Parkinson’s disease among others. Epilepsy as well as brain tumors and neuroinflammatory conditions may benefit from this treatment too. The system that delivers drugs directly from nostrils into brains has potentiality against various neurological disorders including those caused by cancers. This method should help medicines reach where they are needed most since it overcomes limitations like poor permeability across blood-brain barrier (BBB) and general body reactions which result into more effective treatments thus improving patients’ lives.

More exploration is required to develop nasal drug delivery systems, resolve outstanding difficulties and apply preclinical findings in practice. The main points to concentrate on are making the drugs more stable, improving specificity of targeting them, reducing irritation on mucosal surfaces, and verifying safety as well as efficacy for new formulations. A nose-to-brain drug delivery system is seen as a significant breakthrough in neuropharmacology that may open up fresh possibilities of finding cure for nervous system diseases. Scientists hope that by making use of distinct structures within the nasal cavity they will be able to realize this method’s full potential in clinical application.

**A. MECHANISM OF NOSE TO BRAIN DRUG DELIVERY SYSTEM:**

A number of crucial stages are involved in the nose-to-brain medication delivery mechanism, which allows therapeutic drugs to flow via the nasal canal and directly enter the central nervous system (CNS) without passing through the blood-brain barrier (BBB). An outline of the primary mechanisms at play is provided below:

1. **Nasal Absorption:** When medications are administered intranasally, they are deposited in the nasal cavity and interact with the nasal mucosa there. The absorption of drugs into the circulation is facilitated by the nasal mucosa's high surface area and extensive vascularization. This epithelial layer lines the mucosa.

2. **Olfactory Pathway:** The main way for nose-to-brain drug delivery is through the smell pathways. The tissue high up in your nose has special sensors that pick up on smells. These connect right to the brain nerves, getting around the blood brain wall. So drugs that get picked up by the nose sensors can ride along those nerves, hitting the smell part of the brain and other areas. It's a nifty workaround for getting meds directly into the brain without needling through the blood wall. Of course we still breathe most of the drug to the lungs too. But some sneaks up the back nasal passages, catching a lift on the Smelly nerves.
3. **Trigeminal Pathway**: Drugs take more than just the olfactory pathway to impact the brain. The trigeminal nerve, which senses touch, pain, and temperature in the nose also transports drugs to the brain and when drugs hit the nasal lining, they can activate the trigeminal nerve and ride it into different brain areas like the brainstem and cortex. So, the trigeminal nerve gives drugs another road towards shaping brain function aside from our sense of smell. Between olfaction and trigeminal transport, chemicals sniffed into the nose permeate pretty deep into how we think and feel.

4. **Permeation Enhancement**: There's a bunch of ways to try and get drugs to absorb better across the nose’s mucus membranes to reach the brain better. You can add stuff that messes with the membrane's structure some, helping the drug get through easier - things like soapy chemicals or absorption boosters. Or you can stick the drug in tiny nanoparticles or little bubbles called liposomes. Those can both help slip it through the nose and move it along certain brain pathways.

5. **Bypassing the Blood-Brain Barrier**: Drugs can avoid the blood-brain barrier (BBB), which normally restricts the entry of many therapeutic agents into the brain parenchyma, by using the olfactory and trigeminal routes. This makes it possible to deliver medications directly to the central nervous system (CNS), perhaps increasing concentrations at the intended location while lowering systemic exposure and adverse effects.

### B. EXCIPIENTS USED IN NASAL FORMULATION

In nose-to-brain medication delivery systems, excipients are essential for improving the stability of drugs, absorption, targeting, and formulation efficacy overall. The following excipients are frequently included in these formulations:

1. **Permeation Enhancers**: These excipients improve the drug's ability to pass through the nasal mucosa and reach the brain. As examples, consider:
   - **Surfactants**: sorbitan esters (Span 80), polysorbates (Tween 80), and bile salts (sodium taurocholate), among others.
   - **Fatty acids**: they include lauric and oleic acids.
   - **Cyclodextrins**: they include sulfobutylether-beta-cyclodextrin (SBEβCD) and hydroxypropyl-beta-cyclodextrin (HPβCD).

2. **Mucoadhesive Agents**: By promoting the formulation's adherence to the nasal mucosa, these excipients enhance the duration of contact and improve medication absorption. As examples, consider:
   - **Carbomers**: 934 and 974P are two examples of carbomers.
   - **Chitosan**: chitin is the origin of this biopolymer.
   - **Hyaluronic acid**: One glycosaminoglycan present in connective tissues.

3. **Absorption Enhancers**: These excipients improve drug absorption by transiently opening tight junctions between epithelial cells or enhancing paracellular transport. Examples include:
   - **EDTA (ethylene diamine tetraacetic acid)**: a chelating agent that disrupts tight junctions.
   - **Sodium caprate**: a fatty acid derivative that enhances paracellular transport.
   - **N-acetyl cysteine**: a mucolytic agent that reduces mucosal viscosity.

4. **Antioxidants**: These excipients prevent drug degradation caused by oxidative reactions, ensuring formulation stability. Examples include:
   - **Ascorbic acid (vitamin C)**: a water-soluble antioxidant.
   - **α-Tocopherol (vitamin E)**: a lipid-soluble antioxidant.

5. **Preservatives**: These excipients prevent microbial growth and contamination in multidose nasal formulations. Examples include:
   - **Benzalkonium chloride**: a quaternary ammonium compound with antimicrobial properties.
   - **Chlorhexidine gluconate**: a cationic bisbiguanide antiseptic.
6. **Buffers**: These excipients maintain the pH of nasal formulations within a suitable range, ensuring compatibility with nasal mucosa and drug stability. Examples include:
   - **Phosphate buffers**: such as monobasic sodium phosphate and dibasic sodium phosphate.
   - **Citrate buffers**: such as citric acid and sodium citrate.

7. **Solubilizers**: These excipients enhance the solubility of poorly water-soluble drugs in nasal formulations. Examples include:
   - **Polyethylene glycol (PEG)**: a hydrophilic polymer.
   - **Ethanol**: a polar solvent.
   - **Propylene glycol**: a solvent and humectant.

8. **Viscosity Modifiers**: These excipients adjust the viscosity of nasal formulations to optimize nasal administration and drug delivery. Examples include:
   - **Hydroxypropyl methylcellulose (HPMC)**: a cellulose derivative.
   - **Xanthan gum**: a polysaccharide produced by fermentation.
   - **Hydroxyethyl cellulose (HEC)**: a water-soluble polymer.

C. **NASAL FORMULATIONS**

Nasal formulations for nose-to-brain medication delivery systems are made to maximize the nasal cavity's ability to carry drugs to the central nervous system (CNS). These formulations seek to target certain brain areas linked to neurological illnesses, improve medication absorption through the nasal mucosa, and get over the blood-brain barrier (BBB). The following are some typical nasal formulations for nose-to-brain medication delivery:

1. **Nasal Sprays**: Nasal sprays are aqueous or liquid formulations containing drugs dissolved or suspended in a solution. They are administered using metered-dose nasal spray devices and deliver precise doses of the drug to the nasal cavity. Nasal sprays are commonly used for delivering small molecule drugs and biologics to the CNS.

2. **Nasal Drops**: Nasal drops are liquid formulations similar to nasal sprays but are administered as drops into the nostrils using dropper bottles. They are suitable for delivering drugs with low doses or narrow therapeutic windows and can provide controlled and targeted drug delivery to specific regions of the nasal cavity.

3. **Nasal Gels**: Nasal gels are semi-solid formulations containing drugs dispersed in a gel matrix. They provide prolonged contact time with the nasal mucosa, enhancing drug absorption and retention in the nasal cavity. Nasal gels can be formulated with mucoadhesive polymers to improve adhesion to the nasal mucosa and prolong drug release.

4. **Nasal Powders**: Nasal powders are dry powder formulations containing micronized drug particles dispersed in a carrier matrix. They are administered using insufflators or nasal inhalers and offer advantages such as improved stability, ease of handling, and reduced risk of microbial contamination. Nasal powders can be formulated with absorption enhancers to enhance drug permeation across the nasal mucosa.

5. **Nasal Microemulsions**: Nasal microemulsions are isotropic liquid formulations consisting of oil, water, surfactant, and co-surfactant components. They form fine oil-in-water emulsions upon contact with nasal mucosa, facilitating drug absorption and transport to the brain. Nasal microemulsions offer advantages such as enhanced drug solubility, rapid onset of action, and improved bioavailability.

6. **Nasal Nanoparticles**: Nasal nanoparticles are colloidal drug delivery systems consisting of drug-loaded nanoparticles dispersed in a liquid or semi-solid nasal formulation. They are designed to enhance drug stability, permeability, and targeting specificity, enabling efficient delivery of drugs to the CNS. Nasal nanoparticles can be surface-modified with ligands or targeting moieties to facilitate receptor-mediated transport across the nasal epithelium.
7. **Nasal Liposomes:** Nasal liposomes are lipid-based vesicular drug delivery systems containing drugs encapsulated within phospholipid bilayers. They offer advantages such as enhanced drug stability, prolonged circulation time, and targeted delivery to specific brain regions. Nasal liposomes can be surface-functionalized with ligands or antibodies to enhance brain targeting and therapeutic efficacy.

D. **APPROACHES**

Many strategies have been investigated in an effort to develop an efficient nose-to-brain medication delivery system, with the goal of resolving the difficulties involved in avoiding the blood-brain barrier (BBB) and focusing on certain brain areas. Here are a few crucial Approaches:

1. **Direct Nose-to-Brain Pathway:**
   - **Olfactory Pathway:** Exploiting the olfactory nerve pathway, drugs can be delivered directly from the nasal cavity to the olfactory bulb and other regions of the brain associated with olfaction. This pathway bypasses the BBB, allowing for rapid and direct access to the central nervous system.
   - **Trigeminal Pathway:** Utilizing the trigeminal nerve pathway, drugs can be transported from the nasal mucosa to various brain regions, including the brainstem and cerebral cortex. This pathway offers an alternative route for nose-to-brain drug delivery, particularly for larger molecules or drugs with poor olfactory transport.

2. **Nanotechnology-Based Delivery Systems:**
   - **Nasal Nanoparticles:** Nanoparticles loaded with drugs can be engineered to enhance drug stability, solubility, and targeting specificity. Surface modifications with ligands or antibodies can facilitate receptor-mediated transport across the nasal epithelium, improving drug absorption and brain uptake.
   - **Nasal Liposomes:** Liposomal drug delivery systems can encapsulate drugs within phospholipid bilayers, offering protection from enzymatic degradation and enhancing brain targeting. Liposomes can be surface-functionalized with targeting ligands to achieve specific uptake by brain cells or tissues.

3. **Mucoadhesive Formulations:**
   - **Nasal Gels:** Mucoadhesive gels containing drugs can adhere to the nasal mucosa, prolonging contact time and enhancing drug absorption. Mucoadhesive polymers such as chitosan, carbomers, or hyaluronic acid can be incorporated into nasal formulations to improve retention and bioavailability.
   - **Nasal Sprays with Mucoadhesive Polymers:** Nasal spray formulations can be modified with mucoadhesive polymers to enhance nasal retention and drug absorption. These polymers can interact with mucin molecules in the nasal mucus, promoting adhesion and prolonging drug release.

4. **Permeation Enhancers:**
   - **Surfactants and Absorption Enhancers:** Surfactants such as polysorbates or absorption enhancers like fatty acids can disrupt the nasal epithelial barrier, enhancing drug permeation and absorption. These excipients can improve drug bioavailability and brain uptake, particularly for hydrophilic or poorly permeable drugs.

5. **Intranasal Device-Based Delivery:**
   - **Nasal Delivery Devices:** Innovative nasal delivery devices such as nasal sprays, nebulizers, or dry powder inhalers can optimize drug deposition, distribution, and absorption in the nasal cavity. These devices can be engineered to deliver precise doses of drugs and ensure consistent drug delivery to the target site in the brain.

6. **Prodrug Strategies:**
• **Nasal Prodrugs**: Prodrugs can be designed to undergo enzymatic conversion in the nasal mucosa, resulting in the release of active drug molecules. Prodrug strategies can improve drug stability, solubility, and absorption, enhancing nose-to-brain delivery and therapeutic efficacy.

**E. Devices Used for Nasal Spray**

In order to efficiently distribute medication through the nasal sprays depend on a few essential device components. The most popular nasal spray devices are broken down as follows:

1. **Metered-Dose Pump (MDPT)**: This is the heart of most nasal sprays. It's a mechanical pump that, when pressed, releases a precise and consistent dose of medication as a fine mist or spray. The MDPT is often housed within a protective plastic housing.

2. **Container**: This holds the medication solution and connects to the metered-dose pump. It's typically made of glass or plastic and may be opaque or transparent.

3. **Nasal Actuator**: This is the nozzle you insert into your nostril. It can be a simple, straight tip or have a more angled design for better targeting. The actuator is often protected by a cap to maintain hygiene.

4. **Optional Features**: Some nasal sprays may have additional features like:
   - **Priming Mechanism**: This requires a specific action (often a press or twist) before the first use to ensure proper dosing.
   - **Dose Counter**: This helps track the number of sprays used, indicating when it's time for a refill.
   - **Bidirectional Spray**: These sprays can deliver medication to either nostril without needing to turn the container.

**F. Types of Nasal Sprays**

Based on the specific medication and delivery needs, nasal sprays can be categorized into a few types:

- **Unit-Dose Sprays**: These contain a single dose of medication and are discarded after use. They are ideal for precise dosing and hygiene.

- **Multi-Dose Sprays**: These are refillable and contain multiple doses. They are typically more cost-effective but require proper cleaning and hygiene maintenance.

- **Powdered Sprays**: These deliver a dry powder medication instead of a liquid mist. They may be preferred for certain medications or by people who find liquid sprays uncomfortable.

**G. Choosing the Right Nasal Spray**

Though they differ in appearance, all nasal sprays work on the same basic principle: a metering pump that sprays or mists a precise and regulated quantity of medicine. A summary of the typical nasal spray devices is shown below:

1. **Metered Dose Inhalers (MDIs)**:
   - These are the most popular and most common types of nasal spray.
   - They are made out of a canister that holds the drug and propellant, which is often compressed gas.
   - By pressing the actuator, a precise dosage of the drug is released as a thin mist.
   - Prior to initial usage, MDIs frequently need to be primed, and inhalation coordination is required.
2. **Multi-Dose Pumps:**
- The drug solution is kept in a reservoir inside these medical devices.
- With each actuation, a pump mechanism administers a dosage that has been premeasured.
- Although multi-dose pumps are practical and don't need propellant, further cleaning may be necessary to avoid contamination.

3. **Unidose Sprays:**
- A precise dosage of medicine is pre-filled into these single-use nasal sprays.
- After usage, every unit is disposed of, removing any possibility of contamination.
- Compared to refillable alternatives, unidose sprays produce more waste, but they are perfect for accurate dosage and travel.

4. **Nebulizers (for nasal applications):**
- These are less frequent than the other choices, but they can turn liquid medicine into a tiny mist that can be inhaled.
- Usually run on batteries or need an external compressor.
- Patients who have trouble with the coordination needed to use alternative nasal sprays or those who need to administer large amounts of medication might benefit from nasal nebulizers.

---

**EVALUATION OF NASAL DRUG DELIVERY SYSTEMS**

- **In Vitro Testing**
  - **Significance:** Assists in forecasting the drug's diffusion from the formulation via the nasal mucosa in a regulated setting.
  - **Methods:** Drug release rate and penetration through isolated nasal mucosa are measured using methods such as nasal diffusion cells.
  - **Limitations:** The intricacies of the in vivo milieu, such as blood flow, enzymes, and mucociliary clearance, are not entirely replicated.

- **In Vivo Testing**
  - **Significance:** Evaluates the real medication absorption into the circulation following nasal delivery in a living being.
  - **Animal Models:** Dogs, rats, rabbits, and monkeys are frequently utilized, however it's possible that their physiologies don't exactly correspond to our own.
  - **Methods:**
    - Whole animal (in vivo): Nasal administration of the medication is combined with the collection of blood samples to monitor the drug's concentration over time.
    - Isolated Perfused Nasal Cavity (ex vivo): The medication solution is perfused into an isolated nasal cavity to measure mucosal absorption.

- **Bridging The Gap Between In Vitro And In Vivo**
  Create in vitro models that more closely resemble the nasal cavity of a human (human tissue, blood flow). Apply cutting-edge analytical methods to get comprehensive drug-mucosa interaction data. Conduct thoughtful in vivo experiments that take formulation, dosing, and possible degradation into account.

  - **Additional Considerations:**
  - **Computational Modeling:** To simulate drug transport over the nasal mucosa, simulations can be used in conjunction with in vitro and in vivo research.
  - **Physicochemical Properties:** To maximize both testing techniques, it is essential to comprehend the drug's solubility and charge.
- **Safety and Efficacy**: Clinical studies are necessary to assess safety, effectiveness, possible adverse effects, rates of drug absorption, and treatment response.
- **Patient Comfort and Compliance**: In order for a patient to adhere to therapy, it is crucial to consider aspects such as ease of usage and possibility for discomfort.

### METHODOLOGY

- **Literature examination**: To gain an understanding of the present status of nasal medication delivery systems, including the devices, formulations, and delivery methods that are currently in use, start by doing an extensive examination of the literature. Determine knowledge gaps and possible areas for development.

- **Selecting a Drug**: Select a medication or therapeutic agent that is suited for distribution by the nose. Think of things like target location of action, therapeutic indication, physicochemical characteristics, and nasal administration practicality.

- **Formulation Development**: Create a formulation that is best administered by the nose. This might entail maximizing medication concentration and dose form (e.g., solution, suspension, gel, or powder) in addition to choosing excipients to improve drug solubility, stability, and permeability.

- **Preformulation Studies**: To find the best formulation parameters, analyze physicochemical qualities (such as pH, viscosity, and particle size), and establish if the medicine is compatible with excipients, preformulation studies should be conducted.

- **In Vitro Studies**: Conduct in vitro experiments to assess the effectiveness of the nasal medication delivery device. This might entail evaluating the drug's kinetics of release, compatibility with nasal epithelial cells, and permeability across the nasal mucosa as determined by permeation experiments.

- **In Vivo Studies**: Use animal models in in vivo studies to assess the drug's tissue distribution, pharmacokinetics, and pharmacodynamics after nasal delivery. Consider variables like systemic exposure, duration of impact, start of action, and bioavailability.

- **Device Design and Optimization**: Create or pick a suitable nasal delivery device (such as a spray, drop, or powder device) and maximize its features to ensure effective medication administration. Take into account elements like patient convenience, dosage accuracy, spray pattern, and droplet size.

- **Safety and Tolerability Assessment**: Use systemic toxicity, mucociliary clearance, and local tolerance trials to analyze the nasal drug delivery system's safety and tolerability. Keep an eye out for any possible side effects, such as systemic toxicity, congestion, or irritation of the nose.

- **Clinical Studies**: Carry out clinical investigations to evaluate the nasal medication delivery system's patient acceptability, safety, and effectiveness in humans. Analyze factors such treatment results, patient adherence, nasal administration preference versus other routes, and adverse event frequency.

- **Regulatory Considerations**: Make sure that the development and licensing of nasal medication delivery devices complies with all applicable regulations. Prepare and submit documents for approval to regulatory bodies, including preclinical data, clinical trial outcomes, and quality control procedures.

- **Step-Up and Production**: Increase the nasal medication delivery system's output in preparation for its commercial manufacture. To satisfy regulatory requirements and guarantee product efficacy and safety, make sure that formulation, device performance, and quality control procedures are all consistent.

- **Post-Marketing Surveillance**: Using adverse event reports, patient and healthcare professional comments, and post-marketing surveillance studies, track the effectiveness and safety of the nasal drug delivery system after it has been approved.
RESULT AND DISCUSSION

Nasal drug delivery systems (NDDS) present an intriguing and potentially ground-breaking method of administering medicine. The main conclusions, benefits, drawbacks, and potential future paths of NDDS research will all be covered in this work.

Key Findings:

✓ **Bypassing the Blood-Brain Barrier:** NDDS has the ability to deliver medications to the brain directly, getting around the blood-brain barrier (BBB). This provides opportunities for more efficient treatment of neurological conditions.

✓ **Faster Onset of Action:** Nasal sprays have the potential to provide speedier relief for some ailments than oral or intravenous methods.

✓ **Decreased Systemic adverse Effects:** Directly addressing the brain can reduce a drug's exposure to other bodily regions, which may lessen systemic adverse effects.

✓ **Non-invasive Delivery:** Nasal sprays are typically thought to as a practical, non-invasive method of medicine administration that increases patient compliance.

✓ **Difficulties with Drug Absorption:** The kinds and quantities of medications that are appropriate for the nasal cavity are restricted due to its restricted ability to absorb pharmaceuticals.

✓ **Variability in Patient Response:** The effectiveness of medication administration might be impacted by individual variations in nasal architecture and physiology.

✓ **Short Residence Time:** The efficacy of medications can be limited by mucus clearance processes that eliminate them before they fully absorb.

✓ **Possibility of Irritation:** The nasal lining may get irritated by specific excipients or formulations used in nasal sprays.

Discussion

NDDS has a great deal of potential advantages, especially for neurological illnesses and ailments that need to take effect quickly. For broader acceptance, it is imperative to solve the restrictions.

Future Directions:

- **Advanced Formulations:** Studies are being conducted to improve medication targeting, absorption, and residence duration through the use of innovative formulations such liposomes and nanoparticles.

- **Better In Vitro Testing:** Accurate predictions of in vivo performance can be achieved by creating in vitro models that more closely resemble the nasal environment of humans (blood flow, human tissue).

- **Personalized Medicine:** Response rates may be raised by customizing NDDS to each patient's unique anatomy and physiology.

- **Patient Comfort and Compliance:** Creating products and technologies that are easy to use and reduce discomfort is essential to maintaining long-term treatment compliance.

CONCLUSION

One method that appears to be promising for delivering drugs either systemically throughout the body or directly to the brain is nose-to-brain drug delivery (NDDS). It has special benefits such avoiding the blood-brain barrier, acting more quickly, having less systemic adverse effects, and being delivered non-invasively.

NDDS is not without its limits, though. Drug delivery efficiency can be impacted by human diversity in anatomy and physiology, and the nasal canal has a limited capacity for drug absorption. Drugs may be eliminated via mucus clearance processes prior to complete absorption, and certain formulations may irritate the nasal epithelium.

Notwithstanding these obstacles, there is enormous promise for NDDS research. Here's a look at what lies ahead:

- **Advanced Formulations:** Research is being done to improve medication targeting, absorption, and residence duration within the nasal cavity using liposomes and nanoparticles.

- **Improved Testing Procedures:** More accurate forecasts of in vivo performance can be achieved by creating in vitro models that more closely resemble the nasal environment of humans and by applying cutting-edge analytical techniques.
• **Personalized medicine:** By customizing NDDS to each patient's unique features, medication delivery efficiency may be greatly increased.

• **Patient Comfort and Compliance:** In order to ensure long-term treatment compliance, user-friendly equipment and formulations that minimize discomfort are essential.

**ACKNOWLEDGMENT**

This paper and the research behind it would not have been possible without the exceptional support of my supervisor, Prof. Swati R. Borse Assit. Prof. OBVS’s Prof. Ravindra Nikam College of Pharmacy, Gondur Dhule. I also like to express my gratitude to Dr. A. V. Patil Sir, the Principal of Prof. Ravindra Nikam College of Pharmacy Gondur-Dhule, for their unwavering support, research facilities and encouragement.

We would like to express our sincere gratitude to Mr. Pravin Vijay Borse, the head of Game Changer Organization, for his invaluable support and guidance throughout the course of this research project.

**INTEREST CONFLICT**

“The authors claim that the work covered in this book is not at odds with any known financial or personal interests.”

**REFERENCES**


